HIV-Associated Kaposi's Sarcoma
Kaposi's sarcoma (KS) is still one of the most common malignancies in patients with human immunodeficiency virus (HIV) infection. Large randomized clinical trials have shown a protective effect of combination antiretroviral therapy (cART) against the development of KS, even in patients with a r...
Gespeichert in:
| Veröffentlicht in: | Oncology research and treatment 2017-03, Vol.40 (3), p.94-98 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 98 |
|---|---|
| container_issue | 3 |
| container_start_page | 94 |
| container_title | Oncology research and treatment |
| container_volume | 40 |
| creator | Hoffmann, Christian Sabranski, Michael Esser, Stefan |
| description | Kaposi's sarcoma (KS) is still one of the most common malignancies in patients with human immunodeficiency virus (HIV) infection. Large randomized clinical trials have shown a protective effect of combination antiretroviral therapy (cART) against the development of KS, even in patients with a relatively preserved immune system. In patients with sufficient cART, KS has become a rarity. In most patients with HIV-associated KS who initiate cART, the KS lesions stabilize with decreasing HIV plasma viremia and immune reconstitution, or even resolve completely without any specific treatment. In patients with advanced or rapidly progressive disease, especially in the setting of an immune reconstitution syndrome, cART should be combined with cytotoxic chemotherapies. With regard to the KS pathogenesis, several new therapies have been suggested, such as antiviral agents, cytokines, and inhibitors of angiogenesis. |
| doi_str_mv | 10.1159/000455971 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_karge</sourceid><recordid>TN_cdi_karger_primary_455971</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1874783445</sourcerecordid><originalsourceid>FETCH-LOGICAL-c369t-7beadab18de8230512c6534e3c09436076f70029810e9726bc1c265790757bf03</originalsourceid><addsrcrecordid>eNpt0M1LwzAYBvAgihtzB--iAw_qofomab6OY6gbDgY6vYY0TaW62i5pD_73Vlp78vS-hx_PAw9CpxhuMWbqDgBixpTAB2hMiOIRI5wcDr-AEZqG8NEyTBiTQh2jEZGEKSnlGF0sV2_RPITS5qZ26ezJVGXIr8LsxXhbFuYEHWVmF9y0vxP0-nC_XSyj9eZxtZivI0u5qiOROJOaBMvUSUKBYWI5o7GjFlRMOQieCQCiJAanBOGJxZZwJhQIJpIM6ARdd7mVL_eNC7Uu8mDdbme-XNkEjaWIhaRxzFp601HryxC8y3Tl88L4b41B_06ih0lae97HNknh0kH-DdCCyw58Gv_u_AA2z9suQldp1qqzf1Xf8gOpF2wh</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1874783445</pqid></control><display><type>article</type><title>HIV-Associated Kaposi's Sarcoma</title><source>MEDLINE</source><source>Karger Journals</source><source>Alma/SFX Local Collection</source><creator>Hoffmann, Christian ; Sabranski, Michael ; Esser, Stefan</creator><creatorcontrib>Hoffmann, Christian ; Sabranski, Michael ; Esser, Stefan</creatorcontrib><description>Kaposi's sarcoma (KS) is still one of the most common malignancies in patients with human immunodeficiency virus (HIV) infection. Large randomized clinical trials have shown a protective effect of combination antiretroviral therapy (cART) against the development of KS, even in patients with a relatively preserved immune system. In patients with sufficient cART, KS has become a rarity. In most patients with HIV-associated KS who initiate cART, the KS lesions stabilize with decreasing HIV plasma viremia and immune reconstitution, or even resolve completely without any specific treatment. In patients with advanced or rapidly progressive disease, especially in the setting of an immune reconstitution syndrome, cART should be combined with cytotoxic chemotherapies. With regard to the KS pathogenesis, several new therapies have been suggested, such as antiviral agents, cytokines, and inhibitors of angiogenesis.</description><identifier>ISSN: 2296-5270</identifier><identifier>EISSN: 2296-5262</identifier><identifier>DOI: 10.1159/000455971</identifier><identifier>PMID: 28259888</identifier><language>eng</language><publisher>Basel, Switzerland</publisher><subject>Acquired Immunodeficiency Syndrome - diagnosis ; Acquired Immunodeficiency Syndrome - drug therapy ; Acquired Immunodeficiency Syndrome - etiology ; Angiogenesis Inhibitors - administration & dosage ; Anti-Retroviral Agents - administration & dosage ; Antineoplastic Agents - administration & dosage ; Drug Therapy, Combination - methods ; Drug Therapy, Combination - standards ; Evidence-Based Medicine ; Humans ; Medical Oncology - standards ; Practice Guidelines as Topic ; Review Article ; Sarcoma, Kaposi - diagnosis ; Sarcoma, Kaposi - drug therapy ; Sarcoma, Kaposi - etiology ; Treatment Outcome</subject><ispartof>Oncology research and treatment, 2017-03, Vol.40 (3), p.94-98</ispartof><rights>2017 S. Karger GmbH, Freiburg</rights><rights>2017 S. Karger GmbH, Freiburg.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c369t-7beadab18de8230512c6534e3c09436076f70029810e9726bc1c265790757bf03</citedby><orcidid>0000-0002-1082-8093</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,2430,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28259888$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hoffmann, Christian</creatorcontrib><creatorcontrib>Sabranski, Michael</creatorcontrib><creatorcontrib>Esser, Stefan</creatorcontrib><title>HIV-Associated Kaposi's Sarcoma</title><title>Oncology research and treatment</title><addtitle>Oncol Res Treat</addtitle><description>Kaposi's sarcoma (KS) is still one of the most common malignancies in patients with human immunodeficiency virus (HIV) infection. Large randomized clinical trials have shown a protective effect of combination antiretroviral therapy (cART) against the development of KS, even in patients with a relatively preserved immune system. In patients with sufficient cART, KS has become a rarity. In most patients with HIV-associated KS who initiate cART, the KS lesions stabilize with decreasing HIV plasma viremia and immune reconstitution, or even resolve completely without any specific treatment. In patients with advanced or rapidly progressive disease, especially in the setting of an immune reconstitution syndrome, cART should be combined with cytotoxic chemotherapies. With regard to the KS pathogenesis, several new therapies have been suggested, such as antiviral agents, cytokines, and inhibitors of angiogenesis.</description><subject>Acquired Immunodeficiency Syndrome - diagnosis</subject><subject>Acquired Immunodeficiency Syndrome - drug therapy</subject><subject>Acquired Immunodeficiency Syndrome - etiology</subject><subject>Angiogenesis Inhibitors - administration & dosage</subject><subject>Anti-Retroviral Agents - administration & dosage</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Drug Therapy, Combination - methods</subject><subject>Drug Therapy, Combination - standards</subject><subject>Evidence-Based Medicine</subject><subject>Humans</subject><subject>Medical Oncology - standards</subject><subject>Practice Guidelines as Topic</subject><subject>Review Article</subject><subject>Sarcoma, Kaposi - diagnosis</subject><subject>Sarcoma, Kaposi - drug therapy</subject><subject>Sarcoma, Kaposi - etiology</subject><subject>Treatment Outcome</subject><issn>2296-5270</issn><issn>2296-5262</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpt0M1LwzAYBvAgihtzB--iAw_qofomab6OY6gbDgY6vYY0TaW62i5pD_73Vlp78vS-hx_PAw9CpxhuMWbqDgBixpTAB2hMiOIRI5wcDr-AEZqG8NEyTBiTQh2jEZGEKSnlGF0sV2_RPITS5qZ26ezJVGXIr8LsxXhbFuYEHWVmF9y0vxP0-nC_XSyj9eZxtZivI0u5qiOROJOaBMvUSUKBYWI5o7GjFlRMOQieCQCiJAanBOGJxZZwJhQIJpIM6ARdd7mVL_eNC7Uu8mDdbme-XNkEjaWIhaRxzFp601HryxC8y3Tl88L4b41B_06ih0lae97HNknh0kH-DdCCyw58Gv_u_AA2z9suQldp1qqzf1Xf8gOpF2wh</recordid><startdate>20170301</startdate><enddate>20170301</enddate><creator>Hoffmann, Christian</creator><creator>Sabranski, Michael</creator><creator>Esser, Stefan</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1082-8093</orcidid></search><sort><creationdate>20170301</creationdate><title>HIV-Associated Kaposi's Sarcoma</title><author>Hoffmann, Christian ; Sabranski, Michael ; Esser, Stefan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c369t-7beadab18de8230512c6534e3c09436076f70029810e9726bc1c265790757bf03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Acquired Immunodeficiency Syndrome - diagnosis</topic><topic>Acquired Immunodeficiency Syndrome - drug therapy</topic><topic>Acquired Immunodeficiency Syndrome - etiology</topic><topic>Angiogenesis Inhibitors - administration & dosage</topic><topic>Anti-Retroviral Agents - administration & dosage</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Drug Therapy, Combination - methods</topic><topic>Drug Therapy, Combination - standards</topic><topic>Evidence-Based Medicine</topic><topic>Humans</topic><topic>Medical Oncology - standards</topic><topic>Practice Guidelines as Topic</topic><topic>Review Article</topic><topic>Sarcoma, Kaposi - diagnosis</topic><topic>Sarcoma, Kaposi - drug therapy</topic><topic>Sarcoma, Kaposi - etiology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hoffmann, Christian</creatorcontrib><creatorcontrib>Sabranski, Michael</creatorcontrib><creatorcontrib>Esser, Stefan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Oncology research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hoffmann, Christian</au><au>Sabranski, Michael</au><au>Esser, Stefan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HIV-Associated Kaposi's Sarcoma</atitle><jtitle>Oncology research and treatment</jtitle><addtitle>Oncol Res Treat</addtitle><date>2017-03-01</date><risdate>2017</risdate><volume>40</volume><issue>3</issue><spage>94</spage><epage>98</epage><pages>94-98</pages><issn>2296-5270</issn><eissn>2296-5262</eissn><abstract>Kaposi's sarcoma (KS) is still one of the most common malignancies in patients with human immunodeficiency virus (HIV) infection. Large randomized clinical trials have shown a protective effect of combination antiretroviral therapy (cART) against the development of KS, even in patients with a relatively preserved immune system. In patients with sufficient cART, KS has become a rarity. In most patients with HIV-associated KS who initiate cART, the KS lesions stabilize with decreasing HIV plasma viremia and immune reconstitution, or even resolve completely without any specific treatment. In patients with advanced or rapidly progressive disease, especially in the setting of an immune reconstitution syndrome, cART should be combined with cytotoxic chemotherapies. With regard to the KS pathogenesis, several new therapies have been suggested, such as antiviral agents, cytokines, and inhibitors of angiogenesis.</abstract><cop>Basel, Switzerland</cop><pmid>28259888</pmid><doi>10.1159/000455971</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-1082-8093</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2296-5270 |
| ispartof | Oncology research and treatment, 2017-03, Vol.40 (3), p.94-98 |
| issn | 2296-5270 2296-5262 |
| language | eng |
| recordid | cdi_karger_primary_455971 |
| source | MEDLINE; Karger Journals; Alma/SFX Local Collection |
| subjects | Acquired Immunodeficiency Syndrome - diagnosis Acquired Immunodeficiency Syndrome - drug therapy Acquired Immunodeficiency Syndrome - etiology Angiogenesis Inhibitors - administration & dosage Anti-Retroviral Agents - administration & dosage Antineoplastic Agents - administration & dosage Drug Therapy, Combination - methods Drug Therapy, Combination - standards Evidence-Based Medicine Humans Medical Oncology - standards Practice Guidelines as Topic Review Article Sarcoma, Kaposi - diagnosis Sarcoma, Kaposi - drug therapy Sarcoma, Kaposi - etiology Treatment Outcome |
| title | HIV-Associated Kaposi's Sarcoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T22%3A31%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HIV-Associated%20Kaposi's%20Sarcoma&rft.jtitle=Oncology%20research%20and%20treatment&rft.au=Hoffmann,%20Christian&rft.date=2017-03-01&rft.volume=40&rft.issue=3&rft.spage=94&rft.epage=98&rft.pages=94-98&rft.issn=2296-5270&rft.eissn=2296-5262&rft_id=info:doi/10.1159/000455971&rft_dat=%3Cproquest_karge%3E1874783445%3C/proquest_karge%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1874783445&rft_id=info:pmid/28259888&rfr_iscdi=true |